Abstract
Although demonstration of some degree of maternal toxicity is required in regulatory developmental toxicology studies, marked maternal toxicity may be a confounding factor in data interpretation. Reduction in maternal body weight gain is the far most frequently used endpoint of toxicity, but alternative endpoints, like organ toxicity or exaggerated pharmacological response, can also be taken into consideration. The following conclusions are based on literature data and discussions at maternal toxicity workshops attended by representatives from regulatory agencies, academia, and industry: (1) Available results do not support that maternal toxicity (defined as clinical signs, decreased body weight gain or absolute body weight loss of up to 15% in rats or 7% in rabbits) can be used to explain the occurrence of major malformations. (2) There is clear evidence that substantial reductions in maternal weight gain (or absolute weight loss) are linked with other manifestations of developmental toxicity. Among these can be mentioned decreased fetal weight, and skeletal anomalies (e.g., wavy ribs) in rats and decreased fetal weights, post implantation loss, abortions, and some skeletal anomalies in rabbits. (3) There are several examples of misinterpretation among companies, where it was incorrectly expected that regulatory authorities would not label chemicals/drugs as “teratogens/developmental toxicants” because embryo fetal adverse effects were only observed at doses also causing signs of maternal toxicity. (4) Similarly, even if mechanistic studies indicate that a substance causes developmental toxicity via exaggerated pharmacological effects in the mother, such a mechanism does not automatically negate the observed fetal adverse effects.
From a regulatory perspective, an observed developmental toxic finding is considered to be of potential human relevance (even if it is mediated via maternal pharmacological effects or occur at doses causing signs of maternal toxicity) unless the company can provide appropriate mechanistic and/or other convincing evidence to the contrary.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
ICH (2005) Guidance to industry: detection of toxicity to reproduction for medicinal products & toxicity to male fertility S5(R2)
US EPA (1998) Health effects test guidelines. OPPTS 870.3700. Prenatal developmental toxicity study. http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/EPA/EPA_870_3700.pdf. Accessed 24 Aug 2011
OECD (2001) OECD Test Guideline for the Testing of Chemicals. 414 Prenatal developmental toxicity study. http://www.oecd-ilibrary.org/environment/test-no-414-prenatal-development-toxicity-study_9789264070820-en;jsessionid=3s08ej79xtfen.epsilon. Accessed 14 Oct 2012
US FDA Center for Food Safety and Applied Nutrition (2000) Toxicological principles for the safety assessment of food ingredients. Chapter IV.C.9.b. Guidelines for Developmental Toxicity Studies
Khera KS (1984) Maternal toxicity—a possible factor in fetal malformations in mice. Teratology 29:411–416
Khera KS (1985) Maternal toxicity: a possible etiological factor in embryo-fetal death and fetal malformation of rodent-rabbit species. Teratology 31:129–153
Hood RD, Miller DB (2006) Maternally-mediated effects on development. In: Hood RD (ed) Developmental and reproductive toxicology, a practical approach, 2nd edn. CRC, Boca Raton, pp 93–124
Beyer B, Chernoff N, Danielsson BR et al (2011) ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. Birth Defects Res B Dev Reprod Toxicol 92:36–51
Khera KS (1987) Maternal toxicity in humans and animals: effects on fetal development and criteria for detection. Teratog Carcinog Mutagen 7:287–295
Kavlock RJ, Chernoff N, Rogers EH (1985) The effect of acute maternal toxicity on fetal development in the mouse. Teratog Carcinog Mutagen 5:3–13
Chernoff N, Setzer RW, Miller DB et al (1990) Effects of chemically induced maternal toxicity on prenatal development in the rat. Teratology 42:651–658
Chahoud I, Ligensa A, Dietzel L et al (1999) Correlation between maternal toxicity and embryo/fetal effects. Reprod Toxicol 13:75–81
Fleeman TL, Cappon GD, Chapin RE et al (2005) Effects of feed restriction during organogenesis on embryo-fetal development in the rat. Birth Defects Res B Dev Reprod Toxicol 74:42–449
Petrere JA, Rohn WR, Grantham LE et al (1993) Food restriction during organogenesis in rabbits: effects on reproduction and the offspring. Fundam Appl Toxicol 21:517–522
Cappon GD, Fleeman TL, Chapin RE et al (2005) Effects of feed restriction during organogenesis on embryo-fetal development in the rabbit. Birth Defects Res B Dev Reprod Toxicol 74:424–430
Clark RL, Robertson RT, Peter CP et al (1986) Association between adverse maternal and embryo-fetal effects in norfloxacin-treated and food-deprived rabbits. Fundam Appl Toxicol 7:272–286
Organization for Economic Cooperation and Development (OECD) (2007) Draft guidance document on mammalian reproductive toxicity testing and assessment. OECD Environment, Health and Safety Publications, Series on Testing and Assessment, No. 43. http://www.oecd.org/dataoecd/5/61/39813058.pdf. Accessed 25 Aug 2011
US Environmental Protection Agency (EPA) (1991) Guidelines for developmental toxicity risk assessment. Fed Regist 56:63798–63826
Chernoff N, Rogers EH, Gage MI et al (2008) The relationship of maternal and fetal toxicology bioassays with notes on the biological significance of the “no observed adverse effect level”. Reprod Toxicol 25:192–202
Matuzawa T, Nakata M, Goto I et al (1981) Dietary deprivation induces fetal loss and abortion in rabbits. Toxicology 22:255–259
Franklin JB, Brent RB (1964) The effect of uterine vascular clamping on the development of rat embryos three to fourteen days old. J Morphol 115:273–290
Webster WS, Abela D (2007) The effect of hypoxia in development. Birth Defects Res C Embryo Today 81:215–228
Danielsson BR, Reiland S, Rundqvist E et al (1989) Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology 40:351–358
Danielsson BR, Danielson M, Reiland S et al (1990) Histological and in vitro studies supporting decreased uteroplacental blood flow as explanation for digital defects after administration of vasodilators. Teratology 41:185–193
Yoshida T, Kanamori S, Hasegawa Y (1988) Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine. Toxicol Lett 40:127–132
Danielsson BR, Webster WS (1997) Cardiovascular active drugs. In: Kavlock RJ, Daston G (eds) Drug toxicity in embryonic development II; advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants. Springer, Berlin, pp 161–190
Clark RL, Robertson RT, Minsker DH et al (1984) Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. Teratology 30:319–332
Fawcett LB, Buck SJ, Brent RL (1998) Limb reduction defects in the A/J mouse strain associated with maternal blood loss. Teratology 58:183–189
Daston GP, Overmann GJ, Taubeneck MW et al (1991) The role of metallothionein induction and altered zinc status in maternally-mediated developmental toxicity. Comparison of the effects of urethane and styrene in rats. Toxicol Appl Pharmacol 110:450–463
Daston GP, Overmann GJ, Baines D, Taubeneck MW et al (1994) Altered Zn status by alpha-hederin in the pregnant rat and its relationship to adverse developmental outcome. Reprod Toxicol 8:15–24
Schettler T (2008) New conceptual frameworks and challenges in the investigation and practice of environmental reproductive health. Fertil Steril 89:25–26
European Public Assessment Report on revlimid (14 August 2008; updated 17 May 2010). Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/revlimid/revlimid.htm. Accessed 25 Aug 2011
Polak S, Wisnowska B, Brandys J (2009) Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs’ cardiotoxic properties. J Appl Toxicol 29:183–206
Danielsson BR, Danielsson C, Nilsson M (2007) Embryonic cardiac arrhythmia and generaton of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. Reprod Toxicol 24:42–56
Karlsson M, Danielsson BR, Nilsson M et al (2007) New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential. Curr Pharm Des 13:2979–2988
Sköld AC, Danielsson C, Linder B et al (2002) Teratogenicity of the IKr-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 16:333–342
Nilsson MF, Danielsson C, Sköld AC (2010) Astemizole: improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod Toxicol 29:156–163
International Conference on Harmonization (ICH) (2009) Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, M3 (R2)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Danielsson, B.R. (2013). Maternal Toxicity. In: Barrow, P. (eds) Teratogenicity Testing. Methods in Molecular Biology, vol 947. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-131-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-62703-131-8_24
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-130-1
Online ISBN: 978-1-62703-131-8
eBook Packages: Springer Protocols